The Effect of Motivational Interviewing With Video Call in Individuals With Type 2 Diabetes:RCT

Sponsor
Pamukkale University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05628259
Collaborator
Bakırkoy Dr. Sadi Konuk Training and Research Hospital (Other)
70
3
2
5.9
23.3
3.9

Study Details

Study Description

Brief Summary

This study will be carried out to examine the effect of motivational interviewing applied by video call on diabetes self-efficacy, diabetes self-management and metabolic control parameters (HbA1c%, BMI, fasting glucose, cholesterol, blood pressure, waist circumference) in individuals with type 2 diabetes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Motivational Interviewing with WhatsApp video call
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This study is a parallel group randomized controlled study.This study is a parallel group randomized controlled study.
Masking:
Single (Participant)
Masking Description:
Single blinding was provided that included inclusion criteria and agreement to participate in the study.
Primary Purpose:
Supportive Care
Official Title:
The Effect of Motivational Interviewing With Video Call on Diabetes Self-Efficacy, Diabetes Self-Management and Metabolic Control Parameters in Individuals With Type 2 Diabetes: A Randomized Controlled Study
Anticipated Study Start Date :
Jan 2, 2023
Anticipated Primary Completion Date :
Apr 2, 2023
Anticipated Study Completion Date :
Jul 2, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

Behavioral: Motivational Interviewing with WhatsApp video call
The individuals in the intervention group will be given a motivational interview with a WhatsApp video call for 3 months. Motivational interview will be applied every two weeks, 6 times in total.

No Intervention: Control Group

The control group received routine nursing care in the internal diseases policlinic.

Outcome Measures

Primary Outcome Measures

  1. Diabetes Self-Efficacy Scale [Change from Baseline diabetes self-efficacy at 6 months]

    The change in diabetes self efficacy of individuals with Type 2 diabetes at 3rd month and 6 rd month with the Diabetes Self-Efficacy Scale.

  2. Diabetes Self-Management Scale [Change from Baseline diabetes self-management at 6 months]

    This scale was used to measure the behavioral component of individuals in the IMB model. The validity and reliability study of the Turkish Diabetes Self-Management Perception Scale was conducted by Eroğlu and Sabuncu (2018). The scale consists of 16 items and 4 sub-dimensions and is a 4-point Likert type. Glucose Management sub-dimension: Items 4, 6, 10, 12 (items 4 and 12 are about drug use, items 1, 6 and 10 are about blood glucose monitoring). Diet Control sub-dimension: Items 2, 5, 9, 13. Physical Activity sub-dimension: Items 8, 11, 15. Use of Health Services sub-dimension: It consists of 3, 7, 14, and 16 items. The DMS scale consists of 16 items, 7 of which are straight and 9 of which are reversed. The scores of the items numbered "5, 7, 10, 11, 12, 13, 14, 15 and 16" in the scale are calculated by reversing them. Diabetes self-management increases as the score gets closer to 10.

Secondary Outcome Measures

  1. HbA1c% [Change from Baseline HbA1c% at 6 months]

  2. Body Mass Index [Change from Baseline Body Mass Index at 6 months]

  3. Fasting glucose [Change from Baseline Fasting glucose at 6 months]

  4. Cholesterol [Change from Baseline Cholesterol at 6 months]

  5. waist circumference [Change from Baseline waist circumference at 6 months]

  6. Blood pressure [Change from Baseline blood pressure % at 6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 64 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Those between the ages of 30-64

  • Receiving insulin therapy

  • Diagnosed with type 2 diabetes at least six months ago

  • BMI value of 25 and above

  • HbA1c of 8 and above (poor control)

  • At least primary school graduate and can speak Turkish

  • No communication barrier (speech, vision or hearing problem)

  • Having a smart phone and internet access

  • Individuals who agree to participate in the research.

Exclusion Criteria:
  • Communication disability (speech, vision or hearing problem)

  • Those with neuropathy at a level that prevents them from doing their daily physical activities

  • Diagnosed with kidney failure (acute or chronic)

  • Pregnant

  • Those with a diagnosis of cancer

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eda Kılınç İşleyen Pamukkale Denizli Turkey (545)-561 96 83
2 İrem Nur ÖZDEMİR Istanbul Turkey
3 Şengül AYDIN YOLDEMİR Istanbul Turkey

Sponsors and Collaborators

  • Pamukkale University
  • Bakırkoy Dr. Sadi Konuk Training and Research Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
EDA KILINÇ İŞLEYEN, Dr. Research Assistant, Pamukkale University
ClinicalTrials.gov Identifier:
NCT05628259
Other Study ID Numbers:
  • EKILINCISLEYEN
First Posted:
Nov 28, 2022
Last Update Posted:
Nov 28, 2022
Last Verified:
Nov 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 28, 2022